In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography

British Journal of Cancer

Volumn 90, Issue 11, 2004, Pages 2232-2242

  Barthel, H ^a,c   Wilson, H ^a   Collingridge, D R ^a   Brown, G ^a   Osman, S ^a   Luthra, S K ^a   Brady, F ^a   Workman, P ^b   Price, P M ^a   Aboagye, E O ^a,d  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

2 nitroimidazole; Imaging; PET; Tumour hypoxia; 18F FETA

Indexed keywords

CARBOGEN; FLUOROETANIDAZOLE F 18; NITROGEN; NITROREDUCTASE; OCTANOL; TRACER; TUMOR MARKER; UNCLASSIFIED DRUG; WATER; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ETANIDAZOLE; FLUORINE; FLUOROETANIDAZOLE;

AIR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CELL STRAIN MCF 7; CELL TRANSPORT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DISTRIBUTION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOXIA; IMAGING; INSTRUMENTATION; MOUSE; NONHUMAN; PARTITION COEFFICIENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; TISSUE DISTRIBUTION; VALIDATION PROCESS; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL HYPOXIA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXPERIMENTAL NEOPLASM; FIBROSARCOMA; SCINTISCANNING;

ANIMALS; BREAST NEOPLASMS; CELL HYPOXIA; ETANIDAZOLE; FIBROSARCOMA; FLUORINE RADIOISOTOPES; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; TOMOGRAPHY, EMISSION-COMPUTED; TRANSPLANTATION, HETEROLOGOUS;

EID: 3042742567     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601862     Document Type: Article

References (71)

1. Aboagye EO, Kelson AB, Tracy M, Workman P (1998) Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia prob N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. Anti-Cancer Drug Des 13: 703-730
2. Aboagye EO, Lewis AD, Tracy M, Workman P (1997a) Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3- trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554). Biochem Pharmacol 54: 1217-1224
3. Aboagye EO, Maxwell RJ, Kelson AB, Tracy M, Lewis AD, Graham MA, Horsman MR, Griffiths JR, Workman P (1997b) Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia. Cancer Res 57: 3314-3318
4. Adams GE, Clarke ED, Flockhart IR, Jacobs RS, Sehmi DS, Stratford IJ, Wardman P, Watts ME, Parrick J, Wallace RG, Smithen CE (1979) Structure - activity relationship in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency. Int J Radiol Biol 35: 133-150
5. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL (2001) Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916
6. 18F]fluorothymidine as a new marker for monitoring tumor response to anti-proliferative therapy in vivo with positron emission tomography. Cancer Res 63: 3791-3798
7. 18F]Fluoromisonidazole PET and pO2 electrode measurements. Acta Oncol 41: 304-312
8. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56: 941-943
9. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285-289
10. Brown JM, Workman P (1980) Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res 82: 171-190
11. Collingridge DR, Carroll VA, Glaser M, Aboagye EO, Osman S, Hutchinson OC, Barthel H, Luthra SK, Brady F, Bicknell R, Price P, Harris AL (2002) The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62: 5912-5919
12. Collingridge DR, Rockwell S (2000) Pentoxifylline improves the oxygenation and radiation response of BA1112 rat rhabdomyosarcomas and EMT6 mouse mammary carcinomas. Int J Cancer 90: 256-264
13. Collingridge DR, Young WK, Vojnovic B, Wardman P, Lynch EM, Hill SA, Chaplin DJ (1997) Measurement of tumor oxygenation: a comparison between polarographic needle electrodes and a time-resolved luminescence-based optical sensor. Radiat Res 147: 329-334
14. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ, Harris AL (1997) Targeting gene expression to hypoxic tumor cells. Nat Med 3: 515-520
15. Dardzinski BJ, Sotak CH (1994) Rapid tissue oxygen tension mapping using 19F inversion-recovery echo-planar imaging of perfluoro-15-crown-5-ether. Magn Reson Med 32: 88-97
16. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA (2003) In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 30: 844-850
17. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ (1996) 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res 56: 405-411
18. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88: 259-269
19. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A (1997) Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. Nucl Med 38: 1155-1160
20. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP (2002) Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20: 680-687
21. Gräber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91
22. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47
23. Hasegawa T, Rhee JG, Levitt SH, Song CW (1987) Increase in tumor pO2 by perfluorochemicals and carbogen. Int J Radiat Oncol Biol Phys 13: 569-574
24. Helmer KG, Han S, Sotak CH (1998) On the correlation between the water diffusion coefficient and oxygen tension in RIF-1 tumors. NMR Biomed 11: 120-130
25. Höckel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG, Vaupel P (1993) Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26: 45-50
26. Höckel M, Schlenger K, Aral B, Mitze M, Schafer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515
27. Höckel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biological, and molecular aspects. J Natl Cancer Inst 93: 266-276
28. Hollander PM, Ernster L (1975) Studies on the reaction mechanism of DT diaphorase. Action of dead-end inhibitors and effects of phospholipids. Arch Biochem Biophys 169: 560-567
29. Honess DJ, Bleehen NM (1995) Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined. Br J Cancer 71: 1175-1180
30. Honess DJ, Hill SA, Collingridge DR, Edwards B, Brauers G, Powell NA, Chaplin DJ (1998) Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo. Int J Radiat Oncol Biol Phys 42: 731-735
31. Horsman MR, Overgaard J (1992) Overcoming tumour radiation resistance resulting from acute hypoxia. Eur J Cancer 28A: 2084-2085
32. Hoskin PJ, Saunders MI (1994) ARGON. Clin Oncol (Roy Coll Radiol) 6: 281-282
33. Ilangovan G, Li H, Zweier JL, Krishna MC, Mitchell JB, Kuppusamy P (2002) In vivo measurement of regional oxygenation and imaging of redox status in RIF-1 murine tumor: effect of carbogen-breathing. Magn Reson Med 48: 723-730
34. Jeavons AP, Chandler RA, Dettmat CA (1999) A 3D HIDAC-PET camera with sub-millimetre resolution for imaging small animals. IEEE Trans Nucl Sci 46: 468-473
35. Jerabek PA, Patrick TB, Kilbourn MR, Dischino DD, Welch MJ (1986) Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. Int J Radiat Appl Instrum (A) 37: 599-605
36. Joseph P, Jaiswal AK, Stobbe CC, Chapman JD (1994) The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int J Radiat Oncol Biol Phys 29: 351-355
37. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, de Wilde PC, Bussink J, Raleigh JA, van der Kogel AJ (2002) Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62: 7066-7074
38. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, Lindsley KL, Lewellen TK, Krohn KA, Griffin WG (1995) Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33: 391-398
39. Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ, Giaccia AJ (2000) Candidate genes for the hypoxic tumor phenotype. Cancer Res 60: 883-887
40. Leith JT, Michelson S (1995) Secretion rates and levels of vascular endothelial growth factor in clone A or HCT-8 human colon tumour cells as a function of oxygen concentration. Cell Prolif 28: 415-430
41. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI (1991) Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med 32: 1764-1770
42. Moulder JE, Rockwell S (1984) Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 10: 695-712
43. Nordsmark M, Overgaard J (2000) A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 57: 39-43
44. Nordsmark M, Overgaard M, Overgaard J (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31-39
45. Nunn A, Linder K, Strauss HW (1995) Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 22: 265-280
46. Powell ME, Collingridge DR, Saunders MI, Hoskin PJ, Hill SA, Chaplin DJ (1999) Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol 50: 167-171
47. Rasey JS, Casciari JJ, Hofstrand PD, Muzi M, Graham MM, Chin LK (2000) Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res 153: 84-92
48. 18F]Fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 40: 1072-1079
49. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36: 417-428
50. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z (1990) Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 122: 301-308
51. Rockwell S, Moulder JE (1990) Hypoxic fractions of human tumors xenografted into mice: a review. Int J Radiat Oncol Biol Phys 19: 197-202
52. 18F reaction. Radiochim Acta 26: 21-25
53. Seddon BM, Honess DJ, Vojnovic B, Tozer G, Workman P (2001) Measurement of tumor oxygenation: in vivo comparison of a luminescence fibre-optic sensor and a polarographic electrode in the P22 tumors. Radiat Res 55: 837-846
54. Seddon BM, Maxwell RJ, Honess DJ, Grimshaw R, Raynaud F, Tozer GM, Workman P (2002) Validation of the fluorinated 2-nitroimidazole SR-4554 as a non-invasive hypoxia marker detected by magnetic resonance spectroscopy. Clin Cancer Res 8: 2323-2335
55. Semenza GL (2003) Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 54: 17-28
56. Sharp SY, Kelland LR, Valenti MR, Brunton LA, Hobbs S, Workman P (2000) Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol 58: 1146-1155
57. Song CW, Lee I, Hasegawa T, Rhee JG, Levitt SH (1987) Increase in pO2 and radiosensitivity of tumors by Fluosol-DA (20%) and carbogen. Cancer Res 47: 442-446
58. Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, Dannenberg C, Tannapfel A, Sabri O (2003) 18)F]Fluoroazomycinarabinofuranoside ((18)FAZA) and [(18)F]Fluoromisonidazole ((18)FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 30: 317-326
59. Stratford IJ, Workman P (1998) Bioreductive drugs into the next millennium. Anticancer Drug Des 13: 519-528
60. 18F]fluoroetanidazole: a potential new tracer for imaging hypoxia. Nucl Med Biol 24: 755-760
61. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465
62. Walton MI, Smith PJ, Workman P (1991) The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun 3: 199-206
63. Wilson HK (2003) A simplified synthesis of 2,3,5,6-tetrafluorophenyl 2-(2-nitroimidazol-1-yl) acetate. J Labelled Compound Radiopharm 46: 511-513
64. Winski SL, Hargreaves RH, Butler J, Ross D (1998) A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin Cancer Res 4: 3083-3088
65. Workman P (1982) Lipophilicity and the pharmacokinetics of nitroimidazoles. In Advanced Topics on Radiosensitizers of Hypoxic Cells, Breccia A, Rimondi C, Adams GE (eds). pp 143-163. Pienum Press: Amsterdam
66. Workman P, Brown JM (1981) Structure - pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol 6: 39-49
67. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United kingdom coordinating committee on cancer research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77: 1-10
68. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083
69. Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, Podoloff DA (1995) Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 194: 795-800
70. Young WK, Vojnovic B, Wardman P (1996) Measurement of oxygen tension in tumours by time-resolved fluorescence. Br J Cancer 27(Suppl): S256-S259
71. Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT, Karp JS, Alavi A, Dolbier Jr WR, Koch CJ (2003) Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging 30: 259-266